10 Hot Healthcare Stocks To Buy Now

Published on February 3, 2023 at 1:19 pm by Usman Kabir in Hedge Funds, Market Movers, News

In this article, we discuss the 10 hot healthcare stocks to buy now. If you want to read about some more hot healthcare stocks to buy now, go directly to 5 Hot Healthcare Stocks To Buy Now.

The rise of consumer prices has often lagged behind healthcare inflation, which includes costs for doctor visits, surgeries, and prescription drugs. This trend has been especially noticeable during economic downturns, where overall inflation slows while medical prices still rise 2-3%. However, in 2022, the US saw an inflation rate not seen in decades. Even top health stocks like Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV) were affected by this. As healthcare delivery systems faced higher costs due to shortages in areas such as nursing and supplies, consumers felt the same financial pressures during the year.

The healthcare industry faces tough conditions in 2023 due to persistently high inflation and labor shortages. However, a McKinsey report predicts improvement efforts will help the industry overcome these challenges starting in 2024. Certain segments are expected to see higher growth as shifts in profit pools will be affected by several different factors.

The McKinsey report suggests that there will be ongoing growth for healthcare services and technology (HST) profit pools. 2023 is expected to bring robust growth in the sector as providers and payers increase technology adoption. The estimated CAGR for 2021 to 2026 is 10%, reaching $81 billion by 2026. This is an increase from last year’s July estimate, driven by higher demand from payers and providers seeking improved efficiency. This growth makes HST the fastest-growing sector in healthcare. The biggest boost will come from software and platforms.

The pharmacy services sector faced worker shortages and inflationary pressure in 2022. However, 2023 is expected to bring growth. The growth rate is projected to remain steady from 2021 through 2026, reaching $65 billion in profit pools by 2026 from $55 billion in 2021. This growth is mostly due to continued drug utilization and higher specialty drug prices but is partially offset by reimbursement pressure, declining profit margins, and increased specialty generic and biosimilar growth.

AI utilization in healthcare & medicine is surging in 2023. Machine learning can offer data driven CDS to healthcare professionals, leading to increased revenue prospects. AI-powered computers can analyze data at a faster pace, potentially resulting in quicker research advancements. According to Insider Intelligence, AI in healthcare is projected to grow at an annual rate of 48% between 2017 and 2023. The utilization of AI in healthcare holds great promise for enhancing patient outcomes and reducing healthcare expenses. With a growing population, the demand for health services is expected to rise.

Prnewswire.com forecasts that the global telemedicine market will reach $197.55 billion at a CAGR of 24.12% in 2023-2028. Telemedicine offers many benefits, including reducing healthcare costs, improving efficiency and profitability, and providing patients with improved access to medical services. In recent years, telemedicine has seen significant growth. It enables patients to connect with doctors from a distance, reducing the financial burden of healthcare. As a result, many healthcare providers are eager to adopt digital health technologies to take advantage of these benefits.

Total health expenditure is expected to continue on an upward trend across the globe for the next five years. This growth is closely correlated with industry revenues in the health insurance world. However, McKinsey has cautioned that macro uncertainty will persist in part because the enhanced premium subsidies created by the American Rescue Plan Act have expired, and as a result, pricing and consumer participation may face headwinds in the coming months.

Our Methodology

For this article we first used stock screeners to identify healthcare stocks that have gained at least 2% year to date in 2023 and have an average 3-month volume of more than 5 million as of January 31. From this resultant dataset we picked the stocks with highest volumes and share price gains. The list is ranked in ascending order of average 3-month share volume. We also listed the number of hedge funds in each stock so that you can identify the healthcare stocks that are favored by hedge funds.

Photo by CDC on Unsplash

Hot Healthcare Stocks To Buy Now

10. Invitae Corporation (NYSE:NVTA)

Number of Hedge Fund Holders: 20

YTD Perf: 26.88%

Avg Volume: 8.2M

Invitae Corporation (NYSE:NVTA) a medical genetics company, integrates genetic information into mainstream medicine to improve the healthcare of people in the United States, Canada, and internationally. On January 9, Invitae reported preliminary, unaudited financial results for the fourth quarter and full-year 2022, including revenue, cash consumption, and commercial performance metrics. The company generated approximately $516 million in revenue in 2022, which represents a year-over-year growth of approximately 12% from $460 million in 2021. The fourth quarter of 2022 showed a revenue of around $122 million, compared to $126 million in the same period of the previous year.

At the end of the third quarter of 2022, 20 hedge funds in the database of Insider Monkey held stakes worth $129.6 million in Invitae Corporation (NYSE:NVTA), compared to 21 in the preceding quarter worth $189.6 million.

Among the hedge funds being tracked by Insider Monkey, New York-based investment firm Deerfield Management is a leading shareholder in Invitae Corporation (NYSE:NVTA) with 206.9 million shares worth more than $162.2 million.

Just like Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), Invitae Corporation (NYSE:NVTA) is one of the hot healthcare stocks to buy now.

9. Geron Corporation (NASDAQ:GERN)

Number of Hedge Fund Holders: 20

YTD Perf: 36.36%

Avg Volume: 8.5M

Geron Corporation (NASDAQ:GERN) a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. On January 6, Geron Corporation declared the pricing of a larger, underwritten public offering that includes 55,876,297 shares of its common stock being sold at a public offering price of $2.45 per share and pre-funded warrants to purchase 25,000,000 shares of its common stock. The pre-funded warrants are being sold at a public offering price of $2.449 per pre-funded warrant.

At the end of the third quarter of 2022, 16 hedge funds in the database of Insider Monkey held stakes worth $138 million in Geron Corporation (NASDAQ:GERN), compared to 12 in the preceding quarter worth $98.9 million.

Among the hedge funds being tracked by Insider Monkey, Chicago-based investment firm RA Capital Management is a leading shareholder in Geron Corporation (NASDAQ:GERN) with 30 million shares worth more than $70.5 million.

8. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Number of Hedge Fund Holders: 27

YTD Perf: 15.57%

Avg Volume: 9.99M

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a pharmaceutical company, that develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. On January 9, Teva Pharmaceutical Industries announced that it has reached a settlement agreement with 48 US states to resolve allegations that the company played a role in the opioid crisis. The agreement ends claims and lawsuits brought against the company by various state subdivisions, including cities and counties.

On October 20, 2022, Jefferies analyst Glen Santangelo assumed a Hold rating on Teva Pharmaceutical Industries Limited. (NYSE:TEVA) stock at Buy with a $10 price target.

At the end of the third quarter of 2022, 27 hedge funds in the database of Insider Monkey held stakes worth $573 million in Teva Pharmaceutical Industries Limited (NYSE:TEVA), compared to 35 in the preceding quarter worth $733.6 million.

Among the hedge funds being tracked by Insider Monkey, Boston-based investment firm Abrams Capital Management is a leading shareholder in Teva Pharmaceutical Industries Limited (NYSE:TEVA) with 23.9 million shares worth more than $192.9 million.

7. Zomedica Corp. (NYSE:ZOM)

Number of Hedge Fund Holders: 3

YTD Perf: 69.14%

Avg Volume: 10M

Zomedica Corp. (NYSE:ZOM) a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. On January 17, Zomedica Corp announced a partnership with Structured Monitoring Products, Inc. to bring the innovative VetGuardian remote vital signs monitoring system to veterinary professionals. The system operates with zero-touch technology and will be commercially available soon.

On January 6, 2023, Dawson James analyst Jason Kolbert initiated coverage of Zomedica Corp. (NYSE:ZOM) stock with a Buy rating and $6 price target, noting that in the multi-billion dollar worldwide veterinary sector, the company is establishing itself as the top provider of a wide range of goods and services.

At the end of the third quarter of 2022, 3 hedge funds in the database of Insider Monkey held stakes worth $251,000 in Aurora Cannabis Inc. (NASDAQ:ACB), compared to 5 in the previous quarter worth $705,000.

6. Aurora Cannabis Inc. (NASDAQ:ACB)

Number of Hedge Fund Holders: 9

YTD Perf: 12.72%

Avg Volume: 10.7M

Aurora Cannabis Inc. (NASDAQ:ACB) produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. On January 4, Aurora Cannabis Inc. completed the sale of its Aurora Polaris location for a total of roughly $15 million. This was previously announced as part of the company’s ongoing restructuring plan.

On January 27, 2023, Stifel analyst W. Andrew Carter maintained a Hold rating on Aurora Cannabis Inc. (NASDAQ:ACB) stock and lowered the price target to C$1.45 from C$1.75.

At the end of the third quarter of 2022, 9 hedge funds in the database of Insider Monkey held stakes worth $47.7 million in Aurora Cannabis Inc. (NASDAQ:ACB), compared to 10 in the previous quarter worth $45.7 million.

Among the hedge funds being tracked by Insider Monkey, New York-based investment firm Mudrick Capital Management is a leading shareholder in Canopy Growth Corporation (NASDAQ:CGC) with 76.1 million shares worth more than $69.8 million.

In addition to Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), Canopy Growth Corporation (NASDAQ:CGC) is one of the hot healthcare stocks to buy now.

Click to continue reading and see 5 Hot Healthcare Stocks To Buy Now.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on October 30, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

A New Dawn is Coming to U.S. Stocks

Published on November 16, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up